# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2010 Earnings Results

**Report date:** 2010-10-28 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2010

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS — Stock Down 0.22%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -21.66% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about market conditions affecting performance. They reiterated their commitment to research and development despite the current challenges.

**Key quotes:**

> Management highlighted ongoing challenges in the market.

> They emphasized the need for continued investment in R&D.

> There was no clear outlook provided for the upcoming quarters.

### Guidance Changes

No guidance data was provided for future quarters.

### What It Means

This earnings report indicates that Regeneron Pharmaceuticals is facing challenges, as reflected in the missed EPS. The stock reacted slightly down by 0.22%, likely due to the lack of positive news and the absence of forward guidance. Investors may be cautious as the company navigates these market conditions.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2010_